Abstract
The newly isolated hormonal peptide PYY is mainly localized to endocrine cells of the lower intestinal mucosa. The release of PYY by oral glucose was studied in six patients with the dumping syndrome to ascertain the effect of this condition on PYY release. Plasma PYY concentrations were greatly increased following oral glucose in patients with the dumping syndrome compared with healthy controls. In a separate series of experiments, the effect of somatostatin infusion on the PYY release by glucose in these patients was investigated. The release of PYY was completely blocked by infusion of somatostatin, and its release from the bowel in normal subjects may therefore be modulated by local somatostatin in the gut. PYY has been shown to inhibit gastric acid secretion and emptying, at plasma concentrations similar to those seen after glucose, in patients with the dumping syndrome. PYY may therefore be a factor involved in the pathophysiological changes associated with this condition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bloom SR, Royston CMS, Thompson JPS: Enteroglucagon release in the dumping syndrome. Lancet 2:789–791, 1972
Blackburn AM, Christofides ND, Ghatei MA, Sarson DL, Ebeid F, Ralphs DNL, Bloom SR: Elevation of plasma neurotensin in the dumping syndrome. Clin Sci 59:237–243, 1980
Sagor GR, Bryant MG, Ghatei MA, Kirk RM, Bloom SR: Release of vasocative intestinal peptide in the dumping syndrome. Br Med J 282:507–510, 1981
Tatemoto K, Mutt J: Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285:417–418, 1980
Tatemoto K: Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 79:2514–2518, 1982
Adrian TE, Ferri G-L, Barcarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR: Human distribution and release of a putative new gut hormone, peptide YY (PYY). Gastroenterol (in press)
Lundberg JM, Tatemoto K: Vascular effects of the peptides PYY & PHI: Comparison with APP and VIP. Eur J Pharmacol 143:143–146, 1982
Lundberg JM, Tatemoto K, Terenius L, Hellstrom PM, Mutt V, Hokfelt T, Hamberger B: Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc Natl Acad Sci USA 79:4471–4475, 1982
Suzuki J, Nakaya M, Itoh Z, Tatemoto K, Mutt V: Inhibition of interdigestive contractile activity in the stomach by peptide YY in Heidenhaim pouch dogs. Gastroenterology 85:114–121, 1983
Long RG, Adrian TE, Bloom SR: Inhibition of early and late postgastrectomy dumping by somatostatin infusion. Gut 25:557, 1984
El-Salhy M, Grimelius L, Wilander E, Ryberg B, Terenius L, Lundberg JM, Tatemoto K: Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract. Histochemistry 77:15–23, 1983
Bloom SR: Somatostatin and the gut. Gastroenterology 75:145–147, 1978
Adrian TE, Barnes AJ, Long RG, O'Shaughnessy DJ, Brown MR, Rivier J, Vale W, Blackburn AM, Bloom SR: The effect of somatostatin analogs on secretion of growth, pancreatic and gastrointestinal hormones in man. J Clin Endocrinal Metab 53:675–681, 1981
Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR: Effects of peptide YY and neuropeptide on gastric emptying in man. Digestion 30:255–262, 1984
Adrian TE, Savage AP, Sagor GR, Bacarese-Hamilton AJ, Polak JM, Bloom SR: PYY infusion in man, metabolism and secretory effects. Dig Dis Sci 29(Suppl):3S, 1984
Author information
Authors and Affiliations
Additional information
Gastrointestinal Laboratory, St. Thomas Hospital, London SE1 7EH, U.K.
Rights and permissions
About this article
Cite this article
Adrian, T.E., Long, R.G., Fuessl, H.S. et al. Plasma peptide YY (PYY) in dumping syndrome. Digest Dis Sci 30, 1145–1148 (1985). https://doi.org/10.1007/BF01314048
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01314048